Schering Aktiengesellschaft

Jenapharm Gmbh & Co. Kg

Annette Eichardt

Hagen Gerecke

Detlef Grawe

Sabine Gliesing

Peter Hoesel

Uwe Mueller

Peter Hosel

Uwe Muller

Michael Dittgen

Sabine Fricke

Carsten Timpe

The process for making crystals of a 11 &#x3b2;-benzaldoxim-estra-4,9-diene derivative having an average particle size of from 3 &#x3bc;m to 25 &#x3bc;m and a maximum particle size of 100 &#x3bc;m, includes subjecting a supersaturated solution containing a special 11&#x3b2;-benzaldoxim-estra-4,9-diene derivative of formula (I) to a wet milling by a wet milling apparatus while crystallizing, In order to obtain a primary particle suspension. Crystals obtained according to this process and pharmaceutical preparations containing them are also described and are part of the invention.

Process for production of crystals of 11&#x3bc;-benzaldoxim-estra-4,9-diene derivatives, crystals obtained thereby and pharmaceutical preparations containing them

The process for making steroid crystals having a predetermined average particle size of from 1 &#x3bc;m to 25 &#x3bc;m and a maximum particle size that does not exceed a predetermined maximum value of 100 &#x3bc;m, includes subjecting a supersaturated solution containing a steroid to a wet milling by wet milling apparatus while crystallizing, in order to obtain a primary particle suspension. Crystals obtained according to this process and pharmaceutical preparations containing them are also described.

Process for production of steroid crystals, steroid crystals obtained thereby and pharmaceutical preparations containing them

The method of making a solid drug with controlled effective ingredient delivery for oral administration includes selecting a predetermined number of at least three of four compressed compositions containing an effective ingredient or effective ingredient combination defined by their release profile of effective ingredient and/or effective ingredient combination. The solid drug or medicinal preparation is formed according to known methods requiring only comparatively small apparatus expense and minimal time. Perorally administered solid drugs are made by this process which can provide widely varying pharmaceutically-required release profiles of effective ingredients or effective ingredient combinations, for example delayed release, uniformly maintained release or pulsatile release adjusted to fit a special rhythm.

Method of making a perorally administered solid drug with controlled

Growing community of inventors

Buergel, Germany

Annette Eichardt